326030 — SK Biopharmaceuticals Co Balance Sheet
0.000.00%
- KR₩10tn
- KR₩10tn
- KR₩548bn
Annual balance sheet for SK Biopharmaceuticals Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 387,991 | 334,339 | 305,454 | 241,118 | 324,489 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 12,638 | 61,675 | 67,021 | 115,847 | 182,436 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 434,603 | 471,219 | 487,925 | 488,722 | 651,371 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 24,233 | 22,938 | 20,350 | 47,753 | 43,932 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 500,241 | 643,652 | 664,241 | 723,171 | 1,036,811 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 70,595 | 148,306 | 163,073 | 241,619 | 396,276 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 121,175 | 199,465 | 347,681 | 439,484 | 490,538 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 379,067 | 444,187 | 316,560 | 283,686 | 546,273 |
| Total Liabilities & Shareholders' Equity | 500,241 | 643,652 | 664,241 | 723,171 | 1,036,811 |
| Total Common Shares Outstanding |